Study: Treatment patterns in Rheumatoid Arthritis patients n
Researchers described treatment patterns among patients newly initiated on biologic and/or nonbiologic RA therapy over time after enrollment. Understanding the evolving treatment patterns in patients with rheumatoid arthritis (RA) is important for rheumatologists to make the best practice decisions and optimize treatment.

Patients were included in this study if they initiated therapy with conventional synthetic disease-modifying antirheumatic drug (csDMARD) monotherapy, TNF inhibitor (TNFi) monotherapy, other (non-TNFi) biologic monotherapy, or combination therapy (index therapy).

--This study included 8027 patients. csDMARD monotherapy and TNFi + csDMARD combination therapy were the most common index therapies in the registry.

--At therapy initiation, a higher proportion of patients who initiated other biologics, whether as monotherapies or in combination with csDMARD, had high disease activity than those who initiated csDMARD monotherapy.

-- Persistence on a given therapy appeared to decrease for the TNFi monotherapy cohort and other biologic monotherapy cohort over 12?months; switching from one therapy to another was common in the Corrona RA registry.

In the Corrona RA registry, there was an increased shift from one treatment to another and a decline in time for that treatment. It is most likely owing to greater availability of more therapeutic choices and/or a change in the clinical approach, in particular the emphasis on achieving the goals of remission or low activity in combination with more aggressive treatment.